急性淋巴细胞白血病患儿血管内皮生长因子及其受体的表达与临床相关性的初步研究  

Preliminary study of VEGF and its receptor expression on childhood acute lymphoblastic leukemia and its relativity to clinical manifestations

作　　者：梁爱斌[1] 李莉[1] 谢晓恬[1] 江华[2] 叶辉[2] 赵金彩[2] 顾龙君[2] 

机构地区：[1]同济大学附属同济医院血液科,上海200065 [2]上海第二医科大学附属新华医院,儿童医学中心血液科

出　　处：《中华血液学杂志》2005年第8期489-492,共4页Chinese Journal of Hematology

基　　金：国家自然科学青年基金资助项目(30100203)

摘　　要：目的观察不同危险程度分组的急性淋巴细胞白血病(ALL)患儿血管内皮生长因子(VEGF)及其受体F lt-1和KDR的表达及与临床表现、疗效的关系。方法采用ELISA、RT-PCR方法检测正常儿童志愿者(20名)及ALL低危组(29例)、难治组(10例)、缓解组(20例)患儿VEGF及其受体表达,同时对不同分组ALL患儿的临床特点和指标进行参照对比分析。结果难治组患儿VEGF表达[(574.37±208.45)ng/L]高于低危组[(387.93±175.86)ng/L],后者又高于缓解组[(135.80±111.28)ng/L]和正常对照组[(91.16±41.34)ng/L],缓解组与正常对照组比较,差异无统计学意义;VEGF受体mRNA的RT-PCR检测结果从高至低依次为难治组、低危组、缓解组、正常对照组;不同分组VEGF及其受体表达结果与临床表现相吻合。结论高表达VEGF及其受体的患儿往往肿瘤负荷增高,尤其是在难治性ALL患儿中尤为明显,因此VEGF及其受体表达检测可能成为疾病预后的指标之一。Objective To investigate the relationship between differential expression of VEGF and its receptors and clinical characteristics of childhood acute lymphoblastic leukemia (ALL). Methods Expressions of VEGF and its receptors (Flt-1, KDR) were assayed by ELISA and RT-PCR in healthy donors(20 cases), ALL patients in remission(20 cases), with low risk (29 cases) and with high risk (10 cases). The clinical data of all the patients and volunteers enrolled in this study were collected and analyzed according to the expression of VEGF and its receptors. Results The expressions of VEGF were (574.37±208.45) ng/L, (387.93±175.86) ng/L, (135.80±111.28) ng/L and (91.16±41.34) ng/L in patients with high risk, standard risk, in remission and healthy donors, respectively. Expression levels of VEGF receptors were downwards with risk grades. The clinical manifestations were also in accord with the expression levels of VEGF and its receptors. Conclusion ALL patients with highly expressed VEGF and its receptors are usually with higher tumor burden, and refractory treatment. Detection of VEGF and its receptors might be one of prognostic marker for ALL treatment.

关 键 词：急性淋巴细胞白血病 患儿 血管内皮生长因子 受体 表达 

分 类 号：R733.71[医药卫生—肿瘤]